One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Table of Contents
doi : 10.1016/S0923-7534(24)04885-3
Volume 35, Issue 12, December 2024, Pages i-ii
Investigating the ‘liquid–solid interface’ in the comprehensive genomic profiling of metastatic colorectal cancer for guiding treatment—where do we draw the line?
The global epidemic of early-onset cancer: nature, nurture, or both?☆
Inoperable stage III EGFR mutant non-small-cell lung cancer: time for drug first, local later?
Elusive biomarkers of sensitivity to combined PD1/CTLA4 blockade in metastatic castration-resistant prostate cancer
Synthetic lethality in MTAP-deleted tumors: a promising avenue through targeted disruption of the protein methylation pathway
Long-term adjuvant therapy for high-risk GIST: towards tailored imatinib duration?
Lung cancer research and treatment: global perspectives and strategic calls to action
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study☆
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial☆
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration☆
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma☆
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al
Response to letters to the Editor on ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’
Does total neoadjuvant therapy improve overall survival in rectal cancer? Interpretation of the PRODIGE-23 and other studies
Duration of adjuvant imatinib treatment in GIST at high risk of relapse
Reply to the manuscript ‘A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse’ by J.-Y. Blay et al.
Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
Corrigendum to “60P Hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: A phase II trial� [Annals of Oncology 33 (2023) S568]
